My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 108

    1.

    HER2 status in breast cancer--an example of pharmacogenetic testing.

    Kroese M, Zimmern RL, Pinder SE.

    J R Soc Med. 2007 Jul;100(7):326-9. Review.PMID: 17606754 [PubMed - indexed for MEDLINE]Related articles

    2.

    [Assessment of HER2 status in breast cancer]

    Penault-Llorca F, Cayre A.

    Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Review. French. PMID: 15899610 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    HER2--a discussion of testing approaches in the USA.

    Thor A.

    Ann Oncol. 2001;12 Suppl 1:S101-7.PMID: 11521714 [PubMed - indexed for MEDLINE]Related articles

    4.

    HER2 testing recommendations in Australia.

    Bilous M; HER2 Testing Advisory Board.

    Pathology. 2001 Nov;33(4):425-7. Review.PMID: 11827407 [PubMed - indexed for MEDLINE]Related articles

    5.

    High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

    Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

    Mod Pathol. 2008 Oct;21(10):1271-7. Epub 2008 May 16.PMID: 18487992 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    HER2 testing in breast cancer: NCCN Task Force report and recommendations.

    Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

    J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.PMID: 16813731 [PubMed - indexed for MEDLINE]Related articles

    7.

    HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

    O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

    Arch Pathol Lab Med. 2008 Jan;132(1):61-5. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne]. PMID: 18181675 [PubMed - indexed for MEDLINE]Related articles

    8.

    HER2 testing and correlation with efficacy of trastuzumab therapy.

    Fornier M, Risio M, Van Poznak C, Seidman A.

    Oncology (Williston Park). 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 1355-8. Review.PMID: 12435204 [PubMed - indexed for MEDLINE]Related articles

    9.

    Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

    Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

    Breast Cancer. 2001;8(4):316-20. Review.PMID: 11791124 [PubMed - indexed for MEDLINE]Related articles

    10.

    Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.

    Chorn N.

    Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. Review.PMID: 16518442 [PubMed - indexed for MEDLINE]Related articles

    11.

    The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.

    Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ.

    Am J Clin Pathol. 2008 Mar;129(3):383-90.PMID: 18285260 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Should HER2 status be routinely measured for all breast cancer patients?

    Ravdin PM.

    Semin Oncol. 1999 Aug;26(4 Suppl 12):117-23.PMID: 10482203 [PubMed - indexed for MEDLINE]Related articles

    13.

    [HER2 testing for breast cancer. Swedish laboratories can now offer a quality assured analysis of growth factor]

    Haglund M, Chebil G, Johansson L.

    Lakartidningen. 2005 Mar 7-13;102(10):740-3. Swedish. PMID: 15839164 [PubMed - indexed for MEDLINE]Related articles

    14.

    New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.

    Sakamoto G, Mitsuyama S.

    Breast Cancer. 2000;7(4):350-7. No abstract available. PMID: 11114864 [PubMed - indexed for MEDLINE]Related articles

    15.

    Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

    Hicks DG, Kulkarni S.

    Arch Pathol Lab Med. 2008 Jun;132(6):1008-15. Review.PMID: 18517261 [PubMed - indexed for MEDLINE]Related articles

    16.

    [HER2 testing in breast cancer]

    Yoshimura K.

    Nippon Rinsho. 2007 Jun 28;65 Suppl 6:275-80. Review. Japanese. No abstract available. PMID: 17682167 [PubMed - indexed for MEDLINE]Related articles

    17.

    The use of HER2 testing in the management of breast cancer.

    Ravdin P.

    Semin Oncol. 2000 Oct;27(5 Suppl 9):33-42. Review.PMID: 11049055 [PubMed - indexed for MEDLINE]Related articles

    18.

    Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

    Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N.

    J Natl Cancer Inst. 2002 Jun 5;94(11):852-4.PMID: 12048273 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    HER2 testing and correlation with efficacy of trastuzumab therapy.

    Konecny G, Slamon DJ.

    Oncology (Williston Park). 2002 Nov;16(11):1576, 1578. No abstract available. PMID: 12469932 [PubMed - indexed for MEDLINE]Related articles

    20.

    Current status of HER2 testing.

    Di Leo A, Dowsett M, Horten B, Penault-Llorca F.

    Oncology. 2002;63 Suppl 1:25-32. Review.PMID: 12422052 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity